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a b s t r a c t
The endemic malarias threaten the several billion people residing where transmission occurs. Chemo-
therapeutic strategy pitted against these threats hinges upon species- and stage-specific treatments
guided by diagnosis and screening against sometime dangerous contraindications. This approach suits
malaria as it occurs among travelers in the developed, non-endemic world. However, limiting treatment
to that which diagnosis affirms may not be rational in endemic zones. Most of the endemic malarias
remain out of diagnostic reach, either by inaccessibility of the parasite stage, insensitivity of the technol-
ogy, or unavailability of diagnostic services. The partial and fragmented chemotherapeutic attack of
malaria guided by confirmed diagnostics leaves most of the endemic malarias unchallenged. Develop-
ment of elimination therapy, a single course of treatment aimed at all species and stages, would signif-
icantly advance progress against the major killers known collectively as malaria.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. All rights reserved.
1. Introduction
Malariology may be rightfully considered one of the oldest and
most developed technical disciplines among those composing the
broad field called tropical medicine. At least 2 Nobel prizes
(1902; 1908) have been awarded in malariology, and a third
(1927) involved the use of malaria for therapy of tertiary syphilis.
Another (1948) was discovery of the potent insecticide DDT that
proved hugely effective against endemic malaria. The elimination
of endemic malaria from much of North America and Western
Europe during the early 20th century, and a global war in which
malaria posed a serious threat, spawned armies of malariologists
and great strides in the field. Soon after the war, malariologists
marshaled their new tools and marched out an effort to eradicate
malaria (Harrison, 1978). That campaign had tremendous impact
but failed in its ultimate objective. The effort was formally aban-
doned in 1969 and malaria resurged powerfully between 1970
and 2000 (Baird, 2000).
Malaria today shows signs of retreat in many endemic zones
(O’Meara et al., 2008; Behrens et al., 2008; Schmid et al., 2009;
van Rijckevorsel et al., 2010; Prudhomme et al., 2010). The
determinants of this trend may be poorly understood, but the
emergence of strong economic, political, and social commitment
against malaria since around 1995 certainly played a role
(Feachem et al., 2010; Snow et al., 2010; Katz et al., 2011). Those
commitments mobilized three new tools in malaria control: insec-
ticide treated bed nets (ITN), rapid diagnostic tests (RDT), and the
class of antimalarial drugs called the artemisinin-combined thera-
pies (ACT). The fourth key malaria control tool, indoor residual
spraying of insecticide (IRS), was nearly abandoned several dec-
ades ago but today is again emphasized as important (WHO,
2007). These tools, though they have almost certainly diminished
morbidity and mortality due to malaria, may be inadequate to
the far more complex and difficult task of malaria elimination –
the sustained cessation of malaria transmission within a given geo-
graphic area.
In 2008 a sea change in global malaria strategy occurred when
WHO endorsed a call for elimination as a strategic goal versus the
sustainable control of the past four decades. Elimination strategy
aims at, ‘‘. . .progressive elimination from the endemic margins,
to shrink the malaria map.’’ (Feachem, 2009). This strategy hinges
largely upon successful diagnosis and treatment, along with pre-
ventive therapeutics and other interventions aimed at minimizing
human contact with anopheline mosquitoes.
The principle strategic weakness in malaria elimination strategy
may be the view of malaria as a single chemotherapeutic problem
(Baird, 2010). Malaria manifests as many diseases, while ACT aims
only at the acute attack, and principally that of a single species,
Plasmodium falciparum. Many other malarias dominate in most en-
demic zones, and the single chemotherapeutic tool against most of
them is primaquine, a 60-year-old drug. That 8-aminoquinoline,
like others in the class, causes a mild to severe hemolytic anemia
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in patients having an inborn deficiency of glucose-6-phosphate
dehydrogenase (G6PDd) (Beutler and Duparc, 2007). While routine
screening of patients for this abnormality prior to therapy occurs in
developed nations, the vast majority of patients who could benefit
from this therapy, those resident in endemic zones, rarely have
such access. The real risk of harm caused by primaquine, and the
lack of capacities that could protect patients, explains its poor
effectiveness in endemic zones (Baird, 2008).
Elimination of malaria will require chemotherapeutics that
effectively deal with all of the malarias in endemic zones. That
diverse set of infections includes many silent forms: asymptomatic
and sub-patent infections of blood by asexual and sexual stages,
and dormant stages in the liver called hypnozoites. The prevalence
of these silent malarias appears far higher than has been appreci-
ated, especially in zones of relatively very low transmission. Most
of the silent malarias occur beyond the reach of standard and even
state-of-the-art diagnostic technologies. Effective chemotherapeu-
tic attack of them may require abandoning species- and stage-spe-
cific treatment guided by diagnosis as the keystone of malaria
chemotherapeutic strategy and practice.
More than a century of great strides in modern malariology has
not yet provided the technical foundations upon which the ende-
mic malarias may be rationally and effectively attacked. Inade-
quate appreciation of the character of endemic malaria has
driven the neglect of a broad array of essential areas of endeavor
in chemotherapeutics. The developers of chemotherapeutic strate-
gies and tools now have a key role to play in addressing this stra-
tegic weakness. This commentary aims to provide a conceptual
framework for the formulation of chemotherapeutics research
and development agendas aimed at malaria elimination.
2. Global problem
Authoritative agencies and experts, with the following of popu-
lar media, perceive global malaria as an overwhelmingly African
problem dominated by P. falciparum (Finkel, 2007; United Nations,
2005; US CDC, 2011; Kitua et al., 2011). Recent studies, however,
highlight the importance of unrecognized and generally unac-
knowledged burdens of morbidity and mortality associated with
malaria outside of Africa (Hay et al., 2004, 2010; Snow et al.,
2010; Dhingra et al., 2010). Estimates of the mortality burden
caused by malaria as whole, much less any given species, range
across orders of magnitude for mostendemic nations (Dhingra
et al., 2010; Elyazar et al., 2011). The numbers of people at risk
of any malaria in densely populated South and East Asia greatly ex-
ceed those at risk in endemic Africa (Hay et al., 2010; Guerra et al.,
2011). If small children and pregnant women in Africa bear the
brunt of mortality risk associated with malaria, then numbers at
real risk of mortality must exclude a majority of the African popu-
lation at risk of infection. In contrast, while much of Asia may be
accurately characterized as relatively very low intensity transmis-
sion compared to Africa, risk of death with malaria occurs across
demographic groups (Dondorp et al., 2008; Dhingra et al., 2010;
Phu et al., 2010; Sahu et al., 2010; Abu Sayeed et al., 2011).
Recent studies challenging the view of Plasmodium vivax as be-
nign and rarely fatal (Kochar et al., 2005, 2010; Barcus et al., 2007;
Tjitra et al., 2008; Genton et al., 2008; Sharma and Khanduri, 2009;
Valecha et al., 2009; Andrade et al., 2010) emphasize the impor-
tance of considering Asian and American malarias as perhaps sub-
stantial contributors to the global burden of morbidity and
mortality associated with malaria. The global malaria problem
weighs across endemic zones with all of the species and stages of
the parasites responsible for the malarias. Tools that address them
all advance the aim of elimination.
3. The toolbox for malaria
The tools available to national malaria control programs (NMCP)
to strategize for control and elimination impose important limita-
tions. Table 1 summarizes these. In each avenue of implementation,
more research is required to maximize the extent to which NMCPs
may approach interruption of transmission and its permanent elim-
ination as a realistic goal. Despite hundreds of millions of RDTs
being used annually, most malaria in most endemic zones is not
diagnosed, not reported, and very often inadequately treated
(Dhingra et al., 2010; Nsagha et al., 2011; Littrell et al., 2011; Ndo
et al., 2011; Nyandigisi et al., 2011; Yeung et al., 2011; Elyazar
et al., 2011; Mazumdar, 2011; Shaikh and Haran, 2011). Resistance
to the pyrethroid insecticides threatens the effectiveness of ITNs
(Chanda et al., 2011; Himeidan et al., 2011). Moreover, ITNs have
relatively little impact in low transmission settings (Takken,
2002; Sochantha et al., 2006), especially where local mosquito vec-
tors feed predominantly outdoors or in the early evening. The effec-
tiveness of IRS may be limited by either a reluctance to use
inexpensive and long-lasting DDT, or mosquito resistance to it.
NMCPs typically depend upon relatively noxious, toxic, expensive,
and short-lasting pyrethroids, carbamates or organophosphate
insecticides. Those products – developed for and widely used in
the agricultural sector – are also under threat of mosquito resis-
tance. Despite the likely inadequacy of these tools to the task of
elimination, diagnostics and interventions against mosquito vec-
tors accounted for less than 5% of global malaria research expendi-
tures between 2004 and 2009 (PATH, 2011).
Spending on vaccines, drugs and basic research dominated glo-
bal malaria research & development at 87% of spending in 2009
(PATH, 2011). Development of vaccines for malaria suffers a lack
of understanding of acquired immunity to the infection adequate
to rational winnowing of candidate molecules (and their formula-
tion and dosing) prior to phase III clinical trials (PATH, 2011; Baird,
in press). Those trials must be large enough to evaluate protective
efficacy against severe illness and death; the only end points of
importance in the absence of achievable sterilizing immunity.
One protein sub-unit vaccine, RTS, S, in development since 1987
reached phase III trials in 2010/2011. A distinct approach to vacci-
nation involving live parasite challenge followed by suppressive
chemoprophylaxis, achieves sterilizing protection and may thus
be relatively quickly and inexpensively evaluated (Roestenberg
et al., 2011).
Rolling cycles of parasite susceptibility yielding to resistance
drive the continuous and chronically urgent search for new drugs
(White, 2004). The life of any given antimalarial typically ranges
from several years up to several decades, depending on myriad
probable determinants. The one drug that seems to defy this rule,
ancient quinine, may be the most impractical and potentially dan-
gerous of antimalarial drugs (Townsend et al., 2004; Shine and
Coates, 2005; Huston and Levinson, 2006; White, 2007). It is cer-
tainly the most unpleasant from the perspective of the patient,
with serious adherence problems (Achan et al., 2009). Chloroquine,
mefloquine, and the antifolate antimalarials have each in turn fall-
en as front-line therapies against acute attacks of falciparum
malaria. ACTs seem poised to follow (Dondorp et al., 2009).
The generous funding provided to chemotherapeutics thus
stands out as offering greatest promise for delivery of useful tools
in the near future. Diagnostics, drugs, and interventions against the
vector succeeded in eliminating endemic malaria from North
America, most of the Caribbean, Europe, Japan, and numerous
other islands in the Asia Pacific region during the 20th century.
That precedent points to strategy emphasizing improvements to
these tools for the tougher task of accomplishing the same feat
across endemic Oceania, Asia, Africa, and the Americas.
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4. Chemotherapeutics imperatives
No area of endeavor in malaria research and development sup-
porting control and elimination is in greater need of a corrective
course in strategy than chemotherapeutics. This arena has been
dominated by a single imperative over the past six decades: treat-
ment of the acute attack of P. falciparum. The view of malaria as a
global problem almost entirely focused on that parasite and a sin-
gle continent (where the other major cause of malaria, P. vivax, is
relatively rare) surely helps explain this emphasis. Butother key
considerations also come into play: chief among those may be
the ability to continuously maintain discreet lines of the disease-
causing stages of P. falciparum in state-of-the-art laboratories in
North America and Europe. In contrast, the same stages of P. vivax,
and its important dormant liver stage, cannot be thus maintained.
Unless P. vivax becomes similarly tamed to the laboratory, much of
the work committed to this parasite will have to be done within
convenient access to patients in endemic zones. There are compel-
ling reasons to develop such access for chemotherapeutics research
and development, and these are not limited to vivax malaria.
4.1. Malaria of travelers versus residents
Species- and stage-specific treatment of diagnosis-affirmed par-
asite targets in patients underpins malaria chemotherapeutics
strategy and practice. This paradigm, while perfectly suitable for
coping with the relatively rare imported malarias in North America
and Europe, suffers serious drawbacks with respect to chemother-
apeutic management of the many malarias in many millions of
patients in endemic zones. Examination of the fundamental differ-
ences between malaria as it occurs in travelers versus residents
draws attention to critically important issues that are directly
relevant to chemotherapeutics strategy.
In a typical year almost all of the several tens of thousands of re-
ported malaria cases occurring outside of endemic zones have a
diagnosis of a single species of Plasmodium. The majority of these
patients are non-immunes suffering acutemalaria at relatively very
low parasite densities in the blood (Mali et al., 2011). Relatively
sensitive molecular diagnostics, however, detect those low para-
sitemias and are often applied in travelers with suspected malaria.
Although missing that diagnosis sometimes ends tragically
(Alunni-Perret et al., 2010), usually >99% of patients receive appro-
priate treatment and enjoy complete recovery. Among the approx-
imately one-half diagnosed with P. vivax, most (87% (Muhlenberger
et al., 2004)) receive the primaquine required to prevent relapses.
Successful adherence to the 14-day regimen may require emphatic
instruction or supervision. Virtually all patients prescribed primaq-
uine would have been screened for both pregnancy and G6PDd, as
not doing so invites exposure to risk of real harm. In short, travelers
almost always receive chemotherapy informed by necessary labo-
ratory evidence available to their providers.
In sharp contrast, most acute malaria in endemic zones is either
self-treated or managed by a neighbor with some specialized
training (see Section 3). An RDT at this ground level of care deliv-
ery may be available and permit treatment with ACT. If not,
according to the national malaria treatment guidelines of many
endemic countries, the patient will be administered chloroquine
or sulfadoxine/pyramethamine, despite the frequent dominance
of parasites resistant to these drugs. Further, primaquine is rarely
prescribed because screening for G6PDd requires specialized
equipment, laboratory skills, and a cold chain rarely available in
endemic zones. Also, primaquine should not be given to pregnant
women because it threatens the fetus of unknown G6PD status.
The poor practicality of primaquine causes endemic gametocytes
and hypnozoites to very often go unchallenged by any medical
intervention.
In the context of control and especially elimination, silent mal-
arias – those causing no illness and occurring beyond the reach of
diagnostics – represent steep challenges. Infection by hypnozoites
cannot be diagnosed by any standard means and their prevalence
may be very high, even in areas of relatively low transmission.
Douglas et al. (2011) evaluated 10,549 patients in Thailand treated
with experimental therapies for acute P. falciparummalaria: among
those given rapidly excreted drugs, 51% experienced attacks by P.
vivax within 8 weeks. In addition to gametocytes and hypnozoites,
low-density and asymptomatic asexual parasitemias also pose a
significant threat to public health in endemic zones. A blood survey
of over nine thousand people in the Solomon Islands documented
2.7% prevalence by expert microscopy, but 9% by PCR diagnostics
(Harris et al., 2010). Only about 5% of those with parasitemia were
febrile at examination, and most occurred well beyond the diag-
nostic reach of RDTs.
Treatment strictly guided by diagnosis fails to challenge most of
the malarias that apparently dominate endemic zones. The major-
ity occurs beyond diagnostic reach, and the most important tool for
attacking many of them, primaquine, cannot be responsibly ap-
plied for want of a diagnostic device that safely excludes those at
risk harm caused by that therapy. Chemotherapies tailored to
malaria in travelers, informed by diagnostics and thereby partial
and fragmented across species and stages, is not adequate to con-
trolling malaria in endemic zones, much less eliminating it.
4.2. Appropriate therapies
Chemotherapy of malaria in endemic settings must take into ac-
count inadequate access to and sensitivities of diagnostics, the
dominance of silent malarias, and the lack of clinical supervision.
An unsupervised and safely administered single course of treat-
ment effective against all of the malarias represents the strategic
aim. Development of new drugs should be guided by that aim,
but survey of already available drugs also yields possibilities in
the nearer-term.
Table 1
The malaria control and elimination toolbox.
RDT ACT ITN IRS
Name Rapid diagnostic test Artemisinin-combined therapies Insecticide-treated nets Indoor residual spraying
Sector Diagnosis Treatment Prevention Prevention
Application Point-of-care kit suited to
paramedics




Suited to endemic zones Good efficacy against acute
P. falciparum
Suited to endemic zones Passive compliance
Primary
disadvantage
Unable to detect most
asymptomatic
parasitemias
Ineffective against mature sexual
blood stages and dormant liver
stages
Low efficacy without high coverage
rates or in low transmission settings
Requires substantial technical know-
how and organizational infrastructure
Long term
outlook
Less practical and relevant
as transmission declines
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An assembled therapy suited to malaria elimination would in-
clude blood schizontocide(s), hypnozoitocide(s), and gametocyto-
cide(s). Although many candidate blood schizontocides are
available, primaquine (or tafenoquine, an 8-aminoquinoline in
phase III trials in 2011) stands as the only option for the latter
two therapeutic compartments. This brings focus to the primary
problem: what regimen of primaquine may be safely and effec-
tively administered with a blood schizontocide(s) without regard
to offending species and stages of parasite(s) and G6PDd status?
Hypnozoitocidal doses of primaquine providing incidental gameto-
cytocidal coverage simplifies the problem to discovery of dosing
regimens aimed at hypnozoites within the range of safe tolerability
among the most sensitive variants of G6PD. Alternatively, discov-
ery of a point-of-care device for safely excluding those at risk of
harm may suffice. Both avenues merit immediate attention.
5. Chemotherapeutics research rationale
Overcoming the toxicity of primaquine or tafenoquine among
G6PDd patients represents the primary technical objective in
working towards elimination therapies. Avenues of doing so re-
main largely unexplored and at least several now command atten-
tion. Pursuit of these offers bright prospects of important
discoveries and large strides in the ability to attack endemic
malaria.
5.1. G6PDd RDT
Safe exclusion of G6PDd patients from exposure to primaquine
with a point-of-care diagnostic that proves robust in endemic set-
tings has not been pursued until very recently. Such a kit would
certainly permit far broader application of primaquine as currently
prescribed (0.25 or 0.5 mg/kg daily for 14 days), and could open
the possibility of higher doses of shorter duration (e.g., 30 mg 3
times daily for 3 days) for the G6PD-normal majority. Prolonged
dosing certainly curtails effectiveness, especially against a back-
drop of NMCPs that may be reluctant to engage in advocacy for
prescribing and adhering to a potentially harmful therapy against
a silent infection.
RDTs for malaria have proven enormously useful in coping with
acutely ill patients in endemic zones. These simple, durable, and
inexpensive instruments work effectively at the ground level of
healthcare delivery – the relatively impoverished endemic village.
A similar kit for diagnosis of G6PDd would permit the unleashing
of primaquine with greatly mitigated risk of serious harm. The
technical task of fielding such a kit is complex and challenging
due to the currently poor state of the knowledge base that must in-
form such work.
Primaquine sensitivity phenotypes among the hugely diverse
family of clinically significant G6PD mutants remain very poorly
characterized. The phenotype ranges from inconsequential to life
threatening with primaquine challenge. The supposed inverse rela-
tionship between residual enzyme activity and sensitivity to pri-
maquine derives from the presumption of cause-and-effect (the
mechanism of primaquine-induced hemolysis is unknown) and
the primaquine sensitivity phenotypes of just three variants. The
African A-, Mahidol, and Mediterranean B- variants represent mild,
moderate and severe hemolytic sensitivity to primaquine. These
also happen to represent relatively high, moderate, and low levels
of residual enzyme activity, respectively. Whether this correlation
holds across variants has not been systematically evaluated, and at
least some case reports suggest that important exceptions occur
(Ziai et al., 1967). Development of a robust RDT for primaquine
sensitivity based on G6PD activity will require confirmation of
the inverse correlation between that phenotype and residual en-
zyme activity.
Such an RDT will also require coping with other important vari-
ables. G6PDd is X-linked and thus heterozygous among females.
Lyonization of the trait among them creates G6PDd phenotypes
ranging from null to full expression. The kit must also deal with
variable states of acute malaria and anemia and reliably exclude
those at risk of harm, especially if higher doses over shorter dura-
tion are employed to improve primaquine effectiveness. In a stra-
tegic sense, the kit should not aim at diagnosis of G6PDd per se,
but at primaquine ‘‘go/no go’’ decision-making by providers at
the extreme periphery of care delivery. A G6PDd RDT in develop-
ment was recently evaluated in Cambodia with promising results
(Kim et al., 2011).
5.2. Less threatening dosing
Development of less threatening doses of primaquine, though a
complex and nuanced issue, offers promise of substantial and rel-
atively easily gained improvements to safety. Such development
requires consideration of two important and unusual chemothera-
peutic principles with primaquine: the total dose effect, and the
synergistic effects of chloroquine and quinine on hypnozoitocidal
activity.
5.2.1. Total dose effect and dosing strategy
The efficacy of primaquine against relapse hinges on the total
dose delivered with almost no regard to schedule of dosing.
Although evident in some human clinical trials, Schmidt et al.
(1977) demonstrated this principle most convincingly in the Plas-
modium cynomolgi model of relapse in rhesus macaques: the same
total dose of primaquine whether administered as a single dose, or
as smaller doses spread over many weeks showed equal efficacy.
Incremental therapeutic activity against dormant hypnozoites ap-
pears to be irreversible and cumulative to complete efficacy over
at least 8 weeks.
This effect offers great flexibility in dosing, and it was exploited
by the developers of primaquine to field regimens of treatment
with primaquine without the necessity of screening for G6PDd.
The 14-day regimen delivered relatively less threatening doses
and permitted early cessation of dosing. They also developed a reg-
imen intended specifically for G6PDd patients: the single weekly
dose of 45 mg primaquine for 8 weeks (Alving et al., 1960). These
strategies were considered safe for most of the US Army recipients
the developers had in mind, i.e., African-American soldiers with the
African A- variant of G6PDd(safety of that regimen among other
variants of G6PDd has not been evaluated). The total dose effect
of primaquine provides great latitude in adjusting dosing to within
safe tolerability of the most sensitive G6PDd variants. Defining
those limits thus emerges as a vital evidence base for development
of elimination therapies.
5.2.2. Synergism and dose optimizing
The synergism of primaquine activity against hypnozoites by
drugs that otherwise have no known effect on that stage has not
been understood or widely acknowledged. The developers of pri-
maquine recognized the phenomenon at work with pamaquine
(the 8-aminoquinoline predecessor of primaquine) and quinine,
and later conclusively demonstrated it in a clinical trial designed
and executed for that specific purpose (Alving et al., 1955). They
randomized 57 prisoner volunteers to three treatment groups all
experimentally challenged with sporozoites of Chesson strain P. vi-
vax and receiving identical treatments with primaquine (15 mg
daily for 14 days). Two groups of subjects also received identical
daily doses of quinine known to have complete efficacy against
the blood stages of Chesson P. vivax (by therapy of the same using
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volunteers challenged with blood stages), but one group receiving
quinine and primaquine concurrently, and the other group consec-
utively (quinine followed by primaquine after a two day pause).
Relapse occurred in 1 of 19 volunteers receiving concurrent, and
in 15 of 19 receiving consecutive therapies. Four subjects receiving
chloroquine (concurrent with primaquine) relapsed. The experi-
ment demonstrates not only a conspicuously important effect
(concurrent versus consecutive quinine), but also what may be
chemical class-specific synergistic activity (quinine versus chloro-
quine). There may be other compounds with greater synergistic ef-
fects that could be leveraged to deliver less threatening doses of
primaquine. Recent work with tafenoquine showed a 10-fold
reduction in the minimal effective dose against relapse of P. cyno-
molgi in rhesus macaques when administered with blood schizon-
tocide (Dow et al., 2011).
5.3. Strategy
The total dose effect and synergy of primaquine activity provide
means to explore regimens of therapy that do not threaten the
most vulnerable among the G6PDd. Is the lowest possible effective
total dose of primaquine or tafenoquine divisible over a practical
period for safe and efficacious delivery to unscreened G6PDd pa-
tients? Answering this question would directly inform a key ele-
ment of malaria control and elimination strategy. An affirmative
answer would open the possibility of therapies safe and effective
for all of the malarias of endemic zones without regard to diagnos-
tic reach or G6PDd status.
6. Conclusions
Malaria chemotherapeutics research and development over the
past six decades has not taken aim at the endemic malarias. Treat-
ment guided by diagnosis and screening against contraindications
has proven impractical in endemic zones, especially in the case of
primaquine. Despite the wide availability of ACTs, their use is re-
stricted to the diagnosed acute attack. Moreover, these therapies
have not been systematically evaluated for use with primaquine
to achieve the arrest of transmission or the prevention of relapses.
The long neglect of primaquine and the G6PDd problem inhibited
development of elimination chemotherapeutics strategies, but
now offers bright prospects for discovery of practical and effective
applications of primaquine (or tafenoquine) in elimination thera-
pies. The extraordinary total dose and synergistic effects of this
drug may be shrewdly exploited to develop treatments that may
be within range of safe tolerability among patients without diagno-
sis and screening. In short, the chemotherapeutics potential of this
60-year-old drug for endemic zones may be considered effectively
unexplored. Malaria chemotherapists developing evidence leading
to elimination therapies will effectively arm NMCPs with an instru-
ment that radically improves the likelihood of successful elimina-
tion of malaria transmission.
Nonetheless, even quick delivery of a safe and effective elimina-
tion therapy using primaquine or tafenoquine will leave important
gaps. Safety concerns driven by a lack of compelling data will likely
lead to the exclusion of pregnant women and very small children
from its application. If a G6PDd RDT is applied in lieu of universally
safe (and perhaps impractically prolonged) dosing, the G6PDd pa-
tients also become excluded from treatment. In the longer term,
development of therapies that kill hypnozoites and gametocytes
without threatening G6PDd patients should be the highest chemo-
therapeutic imperative for research. The 8-aminoquinolines, it
should be recalled, were discovered and developed before the exis-
tence of the hypnozoitewas known: the chemical universe of hypn-
ozoitocidal possibility may be considered virtually unexplored.
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